fluvastatin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors 1229 93957-54-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lescol
  • fluvastatin
  • leschol
  • fluvastatin sodium
  • XU-62-320
  • fluvastatin sodium salt
  • fluvastatin sodium hydrate
An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.
  • Molecular weight: 411.47
  • Formula: C24H26FNO4
  • CLOGP: 4.05
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 82.69
  • ALOGS: -4.97
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.62 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 24 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.42 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1993 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myalgia 144.65 14.68 138 8736 131887 56151306
Rhabdomyolysis 121.12 14.68 77 8797 40581 56242612
Blood creatine phosphokinase increased 117.26 14.68 66 8808 27886 56255307
Limb reduction defect 101.75 14.68 21 8853 366 56282827
Dysmorphism 73.72 14.68 23 8851 2190 56281003
Cleft palate 72.51 14.68 19 8855 966 56282227
Gamma-glutamyltransferase increased 66.65 14.68 48 8826 30957 56252236
Atrial septal defect 65.66 14.68 28 8846 6478 56276715
Talipes 65.34 14.68 19 8855 1423 56281770
Patent ductus arteriosus 60.66 14.68 23 8851 3928 56279265
Limb hypoplasia congenital 59.52 14.68 12 8862 185 56283008
Antinuclear antibody negative 58.42 14.68 12 8862 204 56282989
Congenital oral malformation 53.72 14.68 11 8863 184 56283009
Coombs positive haemolytic anaemia 52.86 14.68 12 8862 332 56282861
Alanine aminotransferase increased 50.78 14.68 68 8806 93594 56189599
Drug ineffective 50.23 14.68 43 8831 918946 55364247
Retrognathia 49.84 14.68 12 8862 431 56282762
Aspartate aminotransferase increased 49.48 14.68 63 8811 82539 56200654
Herpes simplex reactivation 48.39 14.68 12 8862 488 56282705
Developmental hip dysplasia 45.24 14.68 14 8860 1297 56281896
Myopathy 43.38 14.68 24 8850 9788 56273405
Acute kidney injury 41.09 14.68 106 8768 240657 56042536
Antiphospholipid syndrome 38.35 14.68 13 8861 1608 56281585
Gastritis haemorrhagic 36.02 14.68 12 8862 1407 56281786
Neck deformity 35.45 14.68 13 8861 2022 56281171
Rheumatoid arthritis 34.34 14.68 9 8865 382595 55900598
Lactic acidosis 33.11 14.68 34 8840 35312 56247881
Pancreatitis acute 32.73 14.68 29 8845 25095 56258098
Jaundice 32.60 14.68 30 8844 27264 56255929
Complex regional pain syndrome 31.30 14.68 12 8862 2111 56281082
Anxiety disorder 30.66 14.68 14 8860 3806 56279387
Premature baby 28.74 14.68 24 8850 19181 56264012
Interstitial lung disease 28.74 14.68 40 8834 57023 56226170
Off label use 27.92 14.68 28 8846 556152 55727041
Blood alkaline phosphatase increased 27.01 14.68 32 8842 38913 56244280
Aplasia 26.99 14.68 13 8861 3983 56279210
Muscle spasms 26.03 14.68 63 8811 137308 56145885
Hyperlipidaemia 25.80 14.68 22 8852 18087 56265106
Drug interaction 25.68 14.68 82 8792 209673 56073520
Muscular weakness 25.50 14.68 53 8821 104399 56178794
Alopecia 24.31 14.68 8 8866 293450 55989743
Peripheral swelling 24.17 14.68 4 8870 234722 56048471
Coronary artery disease 22.51 14.68 26 8848 30770 56252423
Joint swelling 22.14 14.68 9 8865 289791 55993402
Pulmonary artery stenosis 21.23 14.68 5 8869 163 56283030
Blood creatinine increased 21.12 14.68 42 8832 80149 56203044
Hypernatraemia 20.84 14.68 13 8861 6607 56276586
Neonatal seizure 20.71 14.68 6 8868 443 56282750
Chromaturia 20.58 14.68 18 8856 15307 56267886
Immunosuppressant drug level increased 20.22 14.68 10 8864 3243 56279950
Haematoma 20.07 14.68 25 8849 31994 56251199
Erysipelas 19.82 14.68 13 8861 7200 56275993
Cerebrovascular accident 19.30 14.68 46 8828 99224 56183969
Otospondylomegaepiphyseal dysplasia 19.26 14.68 4 8870 72 56283121
Angiosclerosis 19.11 14.68 3 8871 9 56283184
Cholestasis 18.47 14.68 22 8852 26891 56256302
Blood urea increased 18.46 14.68 21 8853 24452 56258741
Pleuritic pain 17.66 14.68 12 8862 7045 56276148
Osteonecrosis 17.64 14.68 20 8854 23195 56259998
Product use issue 17.40 14.68 4 8870 186037 56097156
Therapeutic product effect decreased 17.19 14.68 3 8871 169449 56113744
Hepatic cytolysis 17.09 14.68 14 8860 10892 56272301
Bradycardia neonatal 16.90 14.68 6 8868 851 56282342
Cerebral ischaemia 16.69 14.68 11 8863 6139 56277054
Sterile pyuria 16.68 14.68 3 8871 24 56283169
Nephroangiosclerosis 16.66 14.68 4 8870 142 56283051
Hypothyroidism 16.63 14.68 25 8849 38171 56245022
Ocular myasthenia 16.60 14.68 4 8870 144 56283049
Synovitis 16.05 14.68 3 8871 161302 56121891
Foetal exposure during pregnancy 15.97 14.68 23 8851 33800 56249393
Hepatic function abnormal 15.59 14.68 23 8851 34535 56248658
Fasciitis 15.31 14.68 5 8869 551 56282642
Amyotrophic lateral sclerosis 15.29 14.68 6 8868 1122 56282071

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myalgia 275.69 16.09 205 8857 77053 31611229
Blood creatine phosphokinase increased 159.77 16.09 116 8946 41858 31646424
Rectal prolapse 80.90 16.09 20 9042 434 31687848
Intraductal papillary mucinous neoplasm 77.83 16.09 20 9042 510 31687772
Myopathy 75.88 16.09 44 9018 10808 31677474
Renal cyst haemorrhage 75.80 16.09 20 9042 567 31687715
Muscle rupture 71.86 16.09 26 9036 2137 31686145
SARS-CoV-2 antibody test positive 59.08 16.09 15 9047 364 31687918
Vena cava injury 57.34 16.09 14 9048 288 31687994
Abdominal wall haemorrhage 56.69 16.09 15 9047 430 31687852
Carotid arteriosclerosis 54.21 16.09 20 9042 1737 31686545
Vascular anastomotic haemorrhage 53.78 16.09 13 9049 256 31688026
Delayed graft function 53.75 16.09 21 9041 2134 31686148
Aortic dilatation 52.99 16.09 18 9044 1227 31687055
Diverticulum intestinal 52.62 16.09 24 9038 3579 31684703
Off label use 50.91 16.09 18 9044 347256 31341026
Perineal cyst 49.37 16.09 12 9050 242 31688040
Gamma-glutamyltransferase increased 48.13 16.09 49 9013 27776 31660506
Renal artery stenosis 46.89 16.09 19 9043 2123 31686159
Vascular compression 45.42 16.09 12 9050 342 31687940
Mean cell volume increased 44.70 16.09 20 9042 2852 31685430
Restless legs syndrome 42.74 16.09 27 9035 7729 31680553
Hyperparathyroidism secondary 42.34 16.09 16 9046 1485 31686797
Amyotrophic lateral sclerosis 40.83 16.09 14 9048 982 31687300
Aortic arteriosclerosis 40.68 16.09 21 9041 4102 31684180
Actinic keratosis 40.42 16.09 21 9041 4158 31684124
Rhabdomyolysis 38.71 16.09 67 8995 63514 31624768
Hepatosplenomegaly 38.67 16.09 20 9042 3923 31684359
Spinal stenosis 37.90 16.09 21 9041 4727 31683555
Glycosylated haemoglobin increased 37.80 16.09 28 9034 10372 31677910
Intervertebral disc space narrowing 37.56 16.09 13 9049 938 31687344
Vertigo 36.94 16.09 39 9023 23046 31665236
Left ventricular hypertrophy 34.21 16.09 23 9039 7309 31680973
Haemorrhoids 33.48 16.09 28 9034 12354 31675928
Spinal osteoarthritis 32.95 16.09 22 9040 6913 31681369
Arteriosclerosis 32.59 16.09 26 9036 10741 31677541
Myocardial infarction 32.44 16.09 88 8974 113366 31574916
Dysuria 31.89 16.09 37 9025 24257 31664025
Vestibular neuronitis 31.32 16.09 8 9054 199 31688083
Swelling of eyelid 30.63 16.09 11 9051 884 31687398
Blood 25-hydroxycholecalciferol decreased 30.45 16.09 8 9054 223 31688059
Face oedema 28.69 16.09 24 9038 10592 31677690
Toxicity to various agents 27.22 16.09 9 9053 181478 31506804
Tendon rupture 27.00 16.09 19 9043 6500 31681782
Aspartate aminotransferase increased 26.94 16.09 57 9005 62662 31625620
General physical health deterioration 26.63 16.09 82 8980 113353 31574929
Blood potassium increased 26.48 16.09 27 9035 15318 31672964
Death 26.41 16.09 39 9023 360530 31327752
Benign prostatic hyperplasia 26.19 16.09 25 9037 13100 31675182
Angina pectoris 26.05 16.09 37 9025 29604 31658678
Vitamin D decreased 25.63 16.09 14 9048 3063 31685219
Activated partial thromboplastin time prolonged 25.18 16.09 20 9042 8205 31680077
Generalised oedema 25.05 16.09 23 9039 11478 31676804
Febrile bone marrow aplasia 23.85 16.09 19 9043 7827 31680455
Fear 23.80 16.09 21 9041 9953 31678329
Coronary artery disease 23.50 16.09 45 9017 46042 31642240
Hepatic steatosis 23.46 16.09 26 9036 16213 31672069
Squamous cell carcinoma of skin 23.44 16.09 21 9041 10153 31678129
Complications of transplanted kidney 21.28 16.09 14 9048 4291 31683991
Presyncope 20.44 16.09 25 9037 17303 31670979
Product dose omission issue 20.30 16.09 3 9059 105583 31582699
Perioral dermatitis 19.86 16.09 5 9057 117 31688165
Large intestine polyp 19.29 16.09 16 9046 6976 31681306
Seizure 18.80 16.09 3 9059 99765 31588517
Congenital inguinal hernia 18.40 16.09 5 9057 159 31688123
Aortic valve incompetence 18.10 16.09 14 9048 5527 31682755
Chronic kidney disease 18.05 16.09 36 9026 37939 31650343
Myocardial ischaemia 17.99 16.09 23 9039 16644 31671638
Funguria 17.83 16.09 4 9058 56 31688226
Renal cyst 16.73 16.09 16 9046 8400 31679882

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myalgia 324.85 13.71 269 14003 167623 70746549
Blood creatine phosphokinase increased 245.37 13.71 153 14119 61110 70853062
Rhabdomyolysis 113.64 13.71 117 14155 95643 70818529
Myopathy 110.29 13.71 60 14212 18552 70895620
Gamma-glutamyltransferase increased 84.99 13.71 75 14197 50610 70863562
Renal cyst haemorrhage 80.93 13.71 20 14252 624 70913548
Intraductal papillary mucinous neoplasm 76.82 13.71 20 14252 772 70913400
Off label use 75.13 13.71 28 14244 743032 70171140
SARS-CoV-2 antibody test positive 64.27 13.71 15 14257 365 70913807
Aspartate aminotransferase increased 63.57 13.71 101 14171 126877 70787295
Vena cava injury 61.68 13.71 14 14258 300 70913872
Carotid arteriosclerosis 58.49 13.71 21 14251 2406 70911766
Vascular anastomotic haemorrhage 58.32 13.71 13 14259 256 70913916
Rectal prolapse 58.25 13.71 20 14252 2009 70912163
Amyotrophic lateral sclerosis 56.89 13.71 19 14253 1755 70912417
Abdominal wall haemorrhage 56.43 13.71 15 14257 628 70913544
Muscle rupture 54.90 13.71 22 14250 3403 70910769
Perineal cyst 53.70 13.71 12 14260 239 70913933
Delayed graft function 52.13 13.71 21 14251 3292 70910880
Alanine aminotransferase increased 51.33 13.71 100 14172 147380 70766792
Aortic dilatation 50.21 13.71 17 14255 1637 70912535
Actinic keratosis 47.55 13.71 23 14249 5567 70908605
Vascular compression 46.55 13.71 12 14260 445 70913727
Renal artery stenosis 45.49 13.71 19 14253 3265 70910907
Myocardial infarction 45.35 13.71 104 14168 171541 70742631
Aortic arteriosclerosis 40.15 13.71 23 14249 7846 70906326
Coronary artery disease 40.12 13.71 56 14216 62680 70851492
Diverticulum intestinal 39.68 13.71 23 14249 8018 70906154
Hyperparathyroidism secondary 39.51 13.71 16 14256 2542 70911630
Benign prostatic hyperplasia 39.03 13.71 25 14247 10418 70903754
Mean cell volume increased 38.52 13.71 20 14252 5624 70908548
Hepatosplenomegaly 38.43 13.71 20 14252 5650 70908522
Intervertebral disc space narrowing 35.79 13.71 13 14259 1539 70912633
Rheumatoid arthritis 34.86 13.71 8 14264 291797 70622375
Toxicity to various agents 32.88 13.71 18 14254 382154 70532018
Joint swelling 32.19 13.71 6 14266 253205 70660967
Activated partial thromboplastin time prolonged 31.01 13.71 24 14248 13481 70900691
Arteriosclerosis 30.66 13.71 26 14246 16612 70897560
Blood 25-hydroxycholecalciferol decreased 30.14 13.71 8 14264 333 70913839
Left ventricular hypertrophy 29.90 13.71 21 14251 10181 70903991
Blood potassium increased 29.88 13.71 32 14240 27294 70886878
Completed suicide 29.70 13.71 5 14267 227130 70687042
Glycosylated haemoglobin increased 29.66 13.71 26 14246 17365 70896807
Peripheral swelling 29.24 13.71 6 14266 236557 70677615
Death 29.07 13.71 36 14236 510025 70404147
Acute kidney injury 28.57 13.71 178 14094 474446 70439726
Cerebrovascular accident 28.48 13.71 78 14194 143392 70770780
Spinal osteoarthritis 28.31 13.71 24 14248 15324 70898848
Muscular weakness 28.25 13.71 76 14196 138260 70775912
Squamous cell carcinoma of skin 27.91 13.71 22 14250 12690 70901482
Lactic acidosis 27.52 13.71 48 14224 64976 70849196
Myoglobin blood increased 27.32 13.71 13 14259 3034 70911138
Blood alkaline phosphatase increased 27.14 13.71 45 14227 58476 70855696
Muscle spasms 26.93 13.71 80 14192 153966 70760206
Complications of transplanted kidney 26.73 13.71 16 14256 5918 70908254
Infusion related reaction 26.61 13.71 4 14268 197530 70716642
Drug ineffective 26.32 13.71 99 14173 939653 69974519
Haemorrhoids 26.30 13.71 29 14243 25559 70888613
Fear 25.68 13.71 26 14246 20785 70893387
Jaundice 25.24 13.71 40 14232 50068 70864104
Spinal stenosis 25.18 13.71 22 14250 14631 70899541
Vertigo 24.91 13.71 45 14227 62598 70851574
Vestibular neuronitis 24.63 13.71 8 14264 677 70913495
Swelling of eyelid 24.36 13.71 12 14260 3020 70911152
Hyperkalaemia 24.26 13.71 61 14211 106530 70807642
Tendon rupture 23.82 13.71 19 14253 11150 70903022
Blood creatinine increased 23.80 13.71 73 14199 142928 70771244
Face oedema 22.86 13.71 27 14245 25612 70888560
General physical health deterioration 22.80 13.71 101 14171 235930 70678242
Restless legs syndrome 22.70 13.71 23 14249 18405 70895767
Myocardial ischaemia 22.44 13.71 26 14246 24174 70889998
Product dose omission issue 22.21 13.71 8 14264 217460 70696712
Hepatic steatosis 21.33 13.71 30 14242 33783 70880389
Dysuria 20.95 13.71 35 14237 45759 70868413
Blood urea increased 20.88 13.71 35 14237 45874 70868298
Drug interaction 19.85 13.71 138 14134 381303 70532869
Chromaturia 19.71 13.71 24 14248 23504 70890668
Large intestine polyp 19.25 13.71 17 14255 11459 70902713
Muscle necrosis 19.23 13.71 8 14264 1360 70912812
Presyncope 19.01 13.71 30 14242 37408 70876764
Product use in unapproved indication 18.98 13.71 9 14263 207469 70706703
Renal cyst 18.94 13.71 18 14254 13327 70900845
Hepatic function abnormal 18.82 13.71 42 14230 67954 70846218
Aortic valve incompetence 18.67 13.71 15 14257 8889 70905283
General physical condition 18.38 13.71 3 14269 9 70914163
Product use issue 17.73 13.71 7 14265 179930 70734242
Alopecia 17.56 13.71 9 14263 198481 70715691
Angiosclerosis 17.52 13.71 3 14269 13 70914159
Metabolic acidosis 17.39 13.71 43 14229 74303 70839869
Vitamin D decreased 17.26 13.71 14 14258 8413 70905759
Chronic kidney disease 17.22 13.71 38 14234 61019 70853153
Atrioventricular block first degree 17.05 13.71 16 14256 11657 70902515
Perioral dermatitis 17.00 13.71 5 14267 304 70913868
Blood lactate dehydrogenase increased 16.27 13.71 27 14245 35100 70879072
Pancreatitis acute 16.11 13.71 31 14241 45193 70868979
Blood creatine phosphokinase MB 16.06 13.71 3 14269 23 70914149
Immunosuppressant drug level increased 15.90 13.71 13 14259 7894 70906278
Acute myocardial infarction 15.84 13.71 41 14231 72846 70841326
Haematoma 15.82 13.71 32 14240 48386 70865786
Interstitial lung disease 15.19 13.71 51 14221 104634 70809538
Palmoplantar keratoderma 15.16 13.71 5 14267 444 70913728
Febrile bone marrow aplasia 14.83 13.71 15 14257 11976 70902196
Lipids abnormal 13.94 13.71 5 14267 571 70913601
Congenital aortic dilatation 13.71 13.71 3 14269 54 70914118

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AA04 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
HMG CoA reductase inhibitors
FDA MoA N0000000121 Hydroxymethylglutaryl-CoA Reductase Inhibitors
FDA EPC N0000175589 HMG-CoA Reductase Inhibitor
CHEBI has role CHEBI:35679 antilipemic drugs
CHEBI has role CHEBI:77255 lethal toxin inhibitors
CHEBI has role CHEBI:35821 anticholesteremic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Arteriosclerotic vascular disease indication 72092001
Familial hypercholesterolemia - heterozygous indication 238079002
Mixed hyperlipidemia indication 267434003
Slow Progression of Coronary Artery Disease indication
Cerebrovascular accident off-label use 230690007
Myocardial Infarction Prevention off-label use
Primary Prevention of Coronary Heart Disease off-label use
Prevention of Transient Ischemic Attacks off-label use
Alcoholism contraindication 7200002
Low blood pressure contraindication 45007003
Acute nephropathy contraindication 58574008
Disorder of muscle contraindication 129565002 DOID:423
Liver function tests abnormal contraindication 166603001
Hemorrhagic cerebral infarction contraindication 230706003
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Pregnancy, function contraindication 289908002
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
Traumatic injury contraindication 417746004
Uncontrolled Epilepsy contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.05 acidic
pKa2 13.34 acidic
pKa3 13.99 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme INHIBITOR IC50 7.55 CHEMBL DRUG LABEL
Cytochrome P450 2C9 Enzyme IC50 6.40 DRUG MATRIX
Retinoic acid receptor RXR-alpha Nuclear hormone receptor Kd 4.96 CHEMBL
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor WOMBAT-PK
Sodium/bile acid cotransporter Transporter IC50 4.40 CHEMBL
NAD-dependent protein deacetylase sirtuin-6 Unclassified EC50 5.15 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 8.60 CHEMBL

External reference:

IDSource
D00892 KEGG_DRUG
93957-55-2 SECONDARY_CAS_RN
4020854 VANDF
4023909 VANDF
C0082608 UMLSCUI
CHEBI:38561 CHEBI
115 PDB_CHEM_ID
CHEMBL2220442 ChEMBL_ID
CHEMBL1078 ChEMBL_ID
CHEMBL2218894 ChEMBL_ID
D000077340 MESH_DESCRIPTOR_UI
DB01095 DRUGBANK_ID
23663976 PUBCHEM_CID
2951 IUPHAR_LIGAND_ID
6547 INN_ID
4L066368AS UNII
151972 RXNORM
1724 MMSL
189348 MMSL
4757 MMSL
d03183 MMSL
004439 NDDF
004440 NDDF
387585004 SNOMEDCT_US
412392009 SNOMEDCT_US
96307003 SNOMEDCT_US
CHEMBL103585 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
LescolXL HUMAN PRESCRIPTION DRUG LABEL 1 0078-0354 TABLET, EXTENDED RELEASE 80 mg ORAL NDA 30 sections
LescolXL HUMAN PRESCRIPTION DRUG LABEL 1 0078-0354 TABLET, EXTENDED RELEASE 80 mg ORAL NDA 30 sections
Fluvastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-7442 CAPSULE 20 mg ORAL ANDA 26 sections
Fluvastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-7442 CAPSULE 20 mg ORAL ANDA 26 sections
Fluvastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-7443 CAPSULE 40 mg ORAL ANDA 26 sections
Fluvastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-7443 CAPSULE 40 mg ORAL ANDA 26 sections
Fluvastatin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-7446 TABLET, FILM COATED, EXTENDED RELEASE 80 mg ORAL ANDA 28 sections
Fluvastatin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-7446 TABLET, FILM COATED, EXTENDED RELEASE 80 mg ORAL ANDA 28 sections
Fluvastatin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0378-8020 CAPSULE 20 mg ORAL ANDA 26 sections
Fluvastatin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0378-8021 CAPSULE 40 mg ORAL ANDA 26 sections
Fluvastatin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0527-2580 TABLET, FILM COATED, EXTENDED RELEASE 80 mg ORAL ANDA 30 sections
Fluvastatin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0527-2580 TABLET, FILM COATED, EXTENDED RELEASE 80 mg ORAL ANDA 30 sections
FLUVASTATIN SODIUMER HUMAN PRESCRIPTION DRUG LABEL 1 0781-8017 TABLET, EXTENDED RELEASE 80 mg ORAL NDA authorized generic 27 sections
LESCOL HUMAN PRESCRIPTION DRUG LABEL 1 54868-3329 CAPSULE 20 mg ORAL NDA 15 sections
LESCOL HUMAN PRESCRIPTION DRUG LABEL 1 54868-4224 CAPSULE 40 mg ORAL NDA 15 sections
LESCOL XL HUMAN PRESCRIPTION DRUG LABEL 1 54868-4601 TABLET, EXTENDED RELEASE 80 mg ORAL NDA 15 sections
Fluvastatin HUMAN PRESCRIPTION DRUG LABEL 1 63629-8737 CAPSULE 40 mg ORAL ANDA 26 sections
Fluvastatin HUMAN PRESCRIPTION DRUG LABEL 1 63629-8737 CAPSULE 40 mg ORAL ANDA 26 sections
Fluvastatin HUMAN PRESCRIPTION DRUG LABEL 1 63629-8812 CAPSULE 20 mg ORAL ANDA 26 sections
Fluvastatin HUMAN PRESCRIPTION DRUG LABEL 1 63629-8812 CAPSULE 20 mg ORAL ANDA 26 sections
Fluvastatin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 68151-1326 CAPSULE 20 mg ORAL ANDA 25 sections
Fluvastatin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 68151-1334 CAPSULE 40 mg ORAL ANDA 25 sections
Lescol XL HUMAN PRESCRIPTION DRUG LABEL 1 68151-4471 TABLET, EXTENDED RELEASE 80 mg ORAL NDA 26 sections